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Available online 3 December 2016NFKB1, a component of the canonical NF-κB pathway, was recently reported to bemutated in a limited number of
CVID patients. CVID-associatedmutations inNFKB2 (non-canonical pathway) have previously been shown to im-
pair NK cell cytotoxic activity. Although a biological function of NFKB1 in non-human NK cells has been reported,
the role of NFKB1mutations for human NK cell biology and disease has not been investigated yet. We decided
therefore to evaluate the role of monoallelic NFKB1mutations in human NK cell maturation and functions. We
show that NFKB1mutated NK cells present impaired maturation, defective cytotoxicity and reduced IFN-γ pro-
duction upon in vitro stimulation. Furthermore, human IL-2 activated NFKB1 mutated NK cells fail to up-
regulate the expression of the activatingmarker NKp44 and show reduced proliferative capacity. These data sug-
gest that NFKB1 plays an essential novel role for human NK cell maturation and effector functions.
© 2016 Elsevier Inc. All rights reserved.Keywords:
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The NF-κB (NF-kappaB; nuclear factor of kappa light polypeptide
gene enhancer in B cells) signaling pathway plays an important role
both in the innate and the adaptive immune system [1–3]. The NF-κB
transcription factor family consists of ﬁve members: NF-κB1, NF-κB2,
RelA, RelB and c-Rel. NFKB1 encodes the precursor p105 which is proc-
essed to the mature p50. NFKB2 encodes the precursor p100 and the
mature p52. The canonical pathway, which includes NFKB1, mediates
numerous immunological and inﬂammatory cellular responses, and
may be activated upon stimulationwith a broad range of stimuli, includ-
ing proinﬂammatory cytokines, activation of innate immune receptors,
T-cell receptor (TCR) and B-cell receptor (BCR) signaling, and others
[1–3]. The non-canonical pathway, which involves NFKB2, has more re-
stricted immunological functionsmainly focusing on B cell homeostasisnit 1; CVID, Common Variable
unit 2; NK cells, natural killer
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ovirus; EBV, Epstein Barr Virus;
tute of Molecular Medicine “A.
ciences, University of Brescia,and is activated upon engagement of a limited set of members of the
TNF receptor superfamily, including BAFF receptor, CD40 and the
lymphotoxin receptor [2–4].
Data on the NF-κB involvement in NK cell function and maturation
are limited. The ﬁrst indirect description of the biological role of NF-κB
in NK cells was derived from in vitro pharmacological NF-κB inhibition
that led to impaired NK cell cytotoxicity [5]. Studies on Interleukin-2
(IL-2) induced NK cell functional stimulation have implicated the
activation of NF-κB in both, cytotoxic activity and production of
Interferon-gamma (IFN-γ) [6]. However, most of these studies did not
investigate the role of individual components of the NF-κB signaling
pathway. Observations in Nfkb1-deﬁcient mice suggested that p50 is a
negative regulator of NK cell proliferation and IFN-γ production [7].
Primary immunodeﬁciencies provide unique opportunities for a
better understanding of the human immune system. For instance,
congenital mutations in NIK [8] or NEMO [9], both of which encode
upstream components of the NF-κB pathways, have demonstrated
their importance for NK cell function. Monoallelic mutations in
NFKB2, causing a functional haploinsufﬁciency due to expression of
unprocessable p100 precursors have been reported in CVID
patients [10–11] and were shown to impair NK cell cytotoxic activity
[12]. Recently, monoallelic mutations in NFKB1 leading to p50
haploinsufﬁciency have also been reported in three CVID families [13].
However, the impact of these NFKB1mutations in human NK cell biolo-
gy has not been investigated. In the present study, we analyzed NK cell
Table 1
Clinical information of the 7 NFKB1 mutated CVID patients.
Patient ID Nationality Sex Year of
birth
Year of
diagnosis
IgGa IgAa IgMa Clinical features Viral infections
Patient 1 [14] Italian M 1976 1989 160 10 10 Recurrent pulmonary infections, autoimmune thyroiditis,
autoimmune enteropathy, gastric adenoma
No EBV, CMV, HBV, HCV (PCR neg.)
Patient 2b,c
(Fam191_02)
German F 1961 1994
(2008)
670
(251)
30
(b6)
30
(b16)
Pneumonias, necrotizing tonsillitis, autoimmune cytopenia
(ITP, intermittent leukopenia, anemia), splenomegaly,
lymphadenopathy, interstitial lung disease, periodontitis,
multiple liver hemangiomas
Herpes zoster (2 episodes)
CMV viremia (8500 IE/ml) with CMV colitis treated
with valganciclovir; intermittent low grade
EBV + CMV replication
Patient 3b,c
(Fam191_01)
German M 1963 2006 8 5 5 Recurrent sinusitis, recurrent otitis, pneumonia, salmonella enteritis,
autoimmune cytopenia, vitiligo, arthritis, splenomegaly,
lymphadenopathy, granulomatous lung disease, persistent CRP elevation
Herpes zoster (3 episodes)
No EBV, CMV, HBV (PCR neg.); adenovirus + respiratory
virus panel for respiratory infections neg.
Patient 4 [13]
(FamNL1-36)
Dutch F 1961 1991 181 6 48 Recurrent sinusitis, pneumonia, otitis media, severe salmonella enteritis n.a.
Patient 5 [15]
(Fam089II2)
German F 1979 1995
(2006)
629
(441)
b30
(b7)
b30
(2)
Recurrent pulmonary infections, ITP, autoimmune hemolytic anemia,
hepatomegaly, lymphadenopathy
Herpes zoster (2 episodes)
No EBV, CMV, HBV, HCV, HIV, HHV8 (PCR neg.); enteritis
virus panel for chronic diarrhoea neg.
Patient 6 [15]
(Fam830_01)
German M 1956 2003 270 b6 21 Chronic sinusitis, recurrent otitis, pneumonia, skin abscesses,
atopic dermatitis with fungal superinfections, autoimmune enteropathy,
nodular regenerative hyperplasia, splenomegaly, lymphadenopathy,
thrombocytopenia
JC virus encephalitis
Norovirus2 infection with intermittent bloody diarrhoea
Herpes zoster (2 episodes)
EBV reactivation with 1000 copies/ml, no speciﬁc therapy,
on follow-up after 1 y neg.
Patient 7c
(Fam695_01)
German F 1957 1987
(2014)
n.a.
(462)
n.a.
(6)
n.a.
(15)
Recurrent bronchitis and sinusitis, enteropathy, splenomegaly, basal
cell carcinoma, osteoporosis
No EBV, CMV, HBV, HCV (PCR neg.)
Numbers in brackets indicate follow-up examinations.
n.a. not available.
b Patients 2 and 3 are siblings.
a Expressed in mg/dl.
c Not previously described patients.
100
V
.Lougaris
etal./ClinicalIm
m
unology
175
(2017)
99–108
101V. Lougaris et al. / Clinical Immunology 175 (2017) 99–108maturation and effector functions in patients with NFKB1mutations af-
fecting the canonical NF-κB pathway.2. Methods
2.1. Monoclonal antibodies
The ﬁne characterization of surface markers of resting and IL-2
activated NK cells was performed using the following monoclonal anti-
bodies (mAbs) generated in our laboratory (Department of Molecular
and Translational Medicine, University of Brescia), or in the laboratory
directed by A. Moretta (Laboratory of Molecular Immunology, DIMES,
University of Genoa): BAB281 (IgG1, anti-NKp46); AZ20 (IgG1, anti-
NKp30); ON72 (IgG1, anti-NKG2D); C127 and SUS142 (IgG1 and
IgG2b respectively, anti-CD16); C227 (IgG1, anti-CD69); 11PB6 (IgG1,
anti-KIR2DL1/S1); GL183 (IgG1, anti-KIR2DL2/L3/S2); AZ158 (IgG2a,
anti-KIR3DL1/S1/L2); Z199 (IgG2b, anti-CD94/NKG2A); anti-XA147
(IgM, anti-CD57); A6/136 (IgM anti-HLA-I).
The commercially available antibodies used in this study are:
anti-CXCR1 (IgG1, Santa Cruz biotechnologies, Santa Cruz, CA; USA);
anti-NKG2C (IgG2b R&D Systems, MN, USA); anti-hCCR7 (IgG2a R&D
Systems, MN, USA); anti-CD62L (IgG1 R&D Systems, MN, USA);
anti-CD107a PE-labeled; anti-IFN-γ PE- (IgG1, BD-Biosciences,
Pharmingen CA, USA); mixture of FITC–labeled CD3 plus PC5-labeled
CD56, FITC-labeled CD14 and FITC-labeled CD20 (Beckman Coulter,
Immunotech, Marseille, France); anti-human Ki-67 antigen (IgG1,
Dako, Denmark A/S); Annexin V PE (BD-Biosciences, Pharmingen CA,
USA); anti-human Perforin/R-PE (Ancell) and anti-human Granzyme/
R-PE (Enzo-Life Sciences).Fig. 1. Novel NFKB1 mutations in adult CVID patients. Electropherograms showing the
novel monoallelic null NFKB1 mutations for Patient 1 (A), Patients 2 and 3 (siblings) (B),
Patient 6 (C) and Patient 7 (D). Wild type control sequences for the novel NFKB1
monoallelic mutations are shown in the upper panels.2.2. Patients, cell preparations and ﬂow cytometry analysis
Seven (7) CVID patients harboring monoallelic NFKB1 mutations
were included in this study (Table 1). Since Patients 2 and 3 are siblings
and carry the same NFKB1 mutation (Table 1), and due to limitation of
biological material available, only one of the two patients was included
in each set of experiments. Peripheral bloodmononuclear cells (PBMCs)
derived from patients and healthy donors, were obtained from heparin-
ized or EDTA blood by density gradient centrifugation over Ficoll
(Sigma, St. Louis,MO). PBMCswere resuspended in RPMI 1640medium,
supplemented with 2 mM glutamine, 50 μg/ml penicillin, 50 μg/ml
streptomycin and 10% heat-inactivated FCS (Fetal Calf Serum, Sigma,
St. Louis, MO).
To obtain polyclonal NK cell lines, NK lymphocytes were isolated
from PBMCs using negative selection (NK cell isolation Kit, Miltenyi),
then cultured on allogenic irradiated feeder cells in the presence of
600 IU/ml recombinant human IL-2 (Proleukin; Chiron) and 1.5 ng/ml
phytohemagglutinin (GIBCO Ltd) [14].
To perform ﬂow cytometry analysis, PBMCs and IL-2 activated NK
cells derived from peripheral blood were ﬁrst stained with appropriate
primary monoclonal mouse antibodies, followed by PE-conjugated
isotype-speciﬁc goat anti-mouse secondary reagent (Southern Biotech-
nology, Birmingham, AL); cells were subsequently stained with a mix-
ture of FITC-labeled CD3 and PC5-labeled CD56, and FITC-labeled
CD14 and FITC-labeled CD20. NK cells analysis by ﬂow cytometry was
performed by gating on CD56+ CD3− CD14− and CD20− cells. Cell
acquisitionwasperformed on a FACSCantoﬂow cytometer, and data an-
alyzed using the Diva software (Becton Dickinson, Mountain View, CA).
For Annexin V staining, IL-2 activated NK lymphocytes were
resuspended in 1× Binding Buffer (BD Biosciences) at 1–5 × 106/ml
and stained with 5 μl of ﬂuorochrome-conjugated Annexin V PE to
100 μl of cell suspension. Analysis of Annexin Vwas performedby gating
on CD56+CD3− cells. Cells were analyzed on a FACSCanto (BD
Biosciences).2.3. Analysis of NK cell degranulation and IFN-γ production
For degranulation assay against human erythroleukemia cell line
K562, PBMCs derived from patients and from healthy donors were incu-
bated with or without 600 IU/ml rh-IL-2 (Proleukin; Chiron) at 37 °C
overnight. Then, samples were co-incubated with target cells at a ratio
of 1:3 (K562), in a ﬁnal volume of 200 μl in round-bottomed 96-well
plates at 37 °C and 5% CO2 for 3 h in culture medium supplemented
with anti-CD107a-PEmAb. After 1 h of co-incubation, GolgiStop (BD Bio-
sciences Pharmingen, San Diego, CA, USA) was added at a 1:100 dilution.
Surface staining was done by incubating the cells with anti-CD3, anti-
CD14, anti-CD20 and anti-CD56 mAbs for 30 min at 4 °C. Cells were
washed and analyzed by ﬂow cytometry (FACSCanto, Becton Dickinson).
Analysis of NK cells wasmade on CD56+CD3−CD14−CD20− gated cells.
To detect intracellular production of IFN-γ, PBMCs derived from pa-
tients and from healthy donors were incubated overnight at 37 °C with
IL12 (20 ng/ml, Peprotech) plus IL18 (100 ng/ml, Peprotech). Cells were
then washed, ﬁxed and permeabilized with Cytoﬁx/Cytoperm kit (BD
Biosciences Pharmingen). IFN-γ production was detected by subsequent
intracellular staining with anti-IFN-γ-PE antibody (BD Biosciences
Pharmingen) upon gating on CD56+CD3−CD14−CD20− cells. For both
degranulation and IFN-γ expression experiments, the percentage of
positive cells was calculated subtracting the baseline CD107a or IFN-γ
expression in controls cultures in the absence of stimuli (target cells or
cytokines).
2.4. Analysis of cellular proliferation
Cellular proliferation of IL 2 activated NK cells from patients' and
healthy donors' peripheral bloodwas evaluated by detecting intracellular
Fig. 2. Evaluation of peripheral NK cell phenotype from NFKB1 mutated patients. A. Representative dot plots showing percentages of CD56+ NK cells from an NFKB1 mutated
patient and a healthy control (left panel). Scatter plot showing percentages (%) of CD56+ NK cells from NFKB1 mutated patients (n = 6) and healthy controls (CTRs) (n =
10) (right panel). B. Representative dot plot of NKp46 expression on resting CD56+ NK cells from an NFKB1 mutated patient and a healthy control (left panel). Scatter plot
showing NKp46 expression (percentages and mean ﬂuorescence intensity, MFI) on CD56+ NK cells from NFKB1 mutated patients (n = 6) and healthy controls (CTRs) (n =
10) (right panel). C. Representative dot plot of KIRs expression on resting CD56+ NK cells from an NFKB1 mutated patient and a healthy control (left panel). Scatter plot
showing KIRs expression (percentages and MFI) on CD56+ NK cells from NFKB1 mutated patients (n = 6) and healthy controls (CTRs) (n = 10) (right panel). D.
Representative dot plot of CD57 expression on resting CD56dimCD57low (black square) and CD56dimCD57hi (red square) NK cells from an NFKB1 mutated patients and a
healthy control (left panel). Scatter plot showing percentages and MFI of CD57 expression on CD56dim (upper right panel) and CD56bright (lower right panel) NK cells from
NFKB1 mutated patients (n = 6) and healthy controls (HD) (n = 10). Data were obtained from single experiments performed in triplicate and statistical analysis was
performed using the t-student test (* = p b 0,05; ** = p b 0,005).
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(0.1% in PBS) at 4 °C for 20 min. Then cells were incubated with Ki-67
mAb as primary antibody (IgG1, mouse anti-human, 1/40 dilution;
Dako, Copenhagen, Denmark) for 1 h at 4 °C, to detect the nuclear prolif-
eration antigen. The secondary antibody used was PE-conjugated
isotype-speciﬁc goat anti-mouse (Southern Biotechnology, Birmingham,
AL) and was incubated for 30 min at 4 °C, then cells were re-suspended
in 500 μl of PBS solution for ﬂow cytometry analysis.2.5. Mutational analysis
Affected individuals were screened with targeted next
generation sequencing for mutations in known and
prospective genes associated with primary immunodeﬁciencies
as previously described [13]. Sequence variants were veriﬁed
by Sanger sequencing on genomic DNA according to standard
procedures.
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Statistical signiﬁcance was analyzed with the unpaired Student's t-
test by using GraphPad Prism Version 8.0 (GraphPad Software, San
Diego, CA).3. Results
3.1. Patients and novel NFKB1 mutations
Seven adult patients affected with CVID carrying monoallelic NFKB1
mutationswere included in this study. Table 1 summarizes their clinical
and immunological features. All patients presented with recurrent re-
spiratory infections, both of the upper and the lower respiratory tract.
None of the patients presented a history of mycobacterial disease.
Lymphadenopathy and splenomegaly is a frequent feature of this cohort
of patients (4/7 and 4/7 patients, respectively). Autoimmunemanifesta-
tions appeared as prominent features of these NFKB1mutated patients
(6/7 patients) and include autoimmune cytopenias (3/7) and autoim-
mune enteropathy (3/7). Interestingly, 4 out of 7 patients presented a
history of herpes zoster infection, a clinical complication that has not
been reported in patients with NFKB1mutations. Furthermore, Patient
2 presented high grade Cytomegalovirus (CMV) replication with CMV
colitis and low grade Epstein Barr Virus (EBV) replication (Table 1). Pa-
tient 6 suffered from Poliomavirus JC (JCV) encephalitis, intestinal
norovirus infection and EBV reactivation (Table 1).
Two of the affected individuals (Patients 4 and 5) were previously
reported in the ﬁrst description of NFKB1 mutations in CVID [13]. The
remaining ﬁve patients harbor novel monoallelic NFKB1 mutations
(Fig. 1A–D). In detail, Patient 1 harbors a novel frameshift mutation in
exon 15 (c.1517delC) [14], which predicts expression of a truncated
protein (p.Ala506Valfs*17) Patients 2 and 3 are siblings and harbor a
nonsense mutation in exon 14 (c.1356delT), leading to a premature
termination of translation (p.Val456*). Both, Patient 6 (c.496CNT;
p.Arg157*) [15] and Patient 7 (c.295CNT; p.Gln99*) carry nonsenseFig. 3. Expression of CD62L on NFKBI mutated human NK cells. A. Representative dot plots show
patient (upper left panel). Representative dot plots showing percentages of CD56brightCD62Llow
control and anNFKB1mutated patient (lower left panel). B., C., D. Scatter plots showingpercenta
from NFKB1mutated patients (n = 6) and healthy controls (CTRs) (n = 10). Data were obtain
using the t-student test (** = p b 0,005; *** = p b 0,0005).mutations in exon 7 and exon 6, respectively, predicting rapid decay
of the severely truncated proteins and thus, p50 haploinsufﬁciency.
3.2. Impaired human NK cell maturation in the presence of monoallelic
NFKB1 mutations
To determinewhethermonoallelicmutations inNFKB1 affect NK cell
maturation, PBMCs from the index patientswere evaluated bymulticol-
or ﬂow cytometry. All patients presented normal proportions of circu-
lating CD56 NK cells (Fig. 2A). The evaluation of the expression
pattern of activating and inhibitory NK cell receptors, including CD16,
Natural Cytotoxicity Receptors (NCRs) (NKp46, NKp30), KIRs (Killer
cell Immunoglobulin-like Receptors, HLA class I speciﬁc receptors),
NKG2A (inhibitory receptor), NKG2C (activating receptor), CD62L (cell
adhesion molecule), CD57 and chemokine receptors (CXCR1, CCR7)
on human NK cells (both CD56bright and CD56dull subsets) allowed us
to discriminate NK cell subsets based on their maturational and func-
tional status [16]. Precisely, while the percentage of CD56+ NK cells ex-
pressing the NCR NKp30 was similar between patients and controls
(Supplementary Fig. 1), the percentage of CD56+ NK cells expressing
the NCR NKp46 was signiﬁcantly reduced in patients carrying NFKB1
mutations when compared to healthy controls (Fig. 2B). Similar results
were obtained when the expression of KIRs on patients' NK cells was
evaluated: PatientswithNFKB1mutations showed reduced percentages
of CD56+ NK cells expressing KIRs when compared to healthy controls
(Fig. 2C). The expression of CD57, a classical NK maturation marker
[17], showed an interesting pattern (Fig. 2D). The percentages and the
mean ﬂuorescence intensity (MFI) for the CD56dimCD57low NK cell
population were similar in both test groups (Fig. 2D, upper right
panels). In contrast, the CD56dimCD57hi NK cell population was signiﬁ-
cantly reduced in affected individuals with NFKB1 mutations when
compared to healthy controls, both in terms of percentages and MFI
(Fig. 2D, lower right panels).
CD62L belongs to the selectin family proteins and represents an
additional marker for human NK cell maturation [17]. The expression
of this marker on NFKB1mutated NK cells showed an accumulation ofing expression of CD62L on CD56+NK cells from a healthy control and anNFKB1mutated
(red square), CD56brightCD62Lhi (blue square) and CD56dimCD62L+NK cells from a healthy
ges andMFI for CD56brightCD62Llow (B), CD56brightCD62Lhi (C) andCD56dimCD62L+ (D)NK
ed from single experiments performed in triplicate and statistical analysis was performed
Fig. 4. Expression of CXCR1, CCR7, CD16 on NFKBI mutated human NK cells. A. Representative expression of CXCR1 on CD56+ NK cells from a healthy control and an NFKB1 mutated
patient. Scatter plot showing CXCR1 expression (percentages and MFI) on CD56+ NK cells from NFKB1 mutated patients (n = 6) and healthy controls (CTRs) (n = 10). B.
Representative expression of CCR7 on CD56+ NK cells from a healthy control and an NFKB1 mutated patient. Scatter plot showing CCR7 expression (percentages and MFI) on CD56+
NK cells from NFKB1 mutated patients (n = 6) and healthy controls (CTRs) (n = 10). C. Representative expression of CD16 on CD56+ NK cells from a healthy control and an NFKB1
mutated patient. Scatter plot showing CD16 expression (percentages and MFI) on CD56+ NK cells from NFKB1 mutated patients (n = 6) and healthy controls (CTRs) (n = 10). Data
were obtained from single experiments performed in triplicate and statistical analysis was performed using the t-student test (** = p b 0,005).
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controls (Fig. 3A and B). The proportion of the CD56brightCD62Lhi popula-
tion among the NK cells with NFKB1mutations was variable when com-
pared to healthy controls; however, the MFI of CD62L within this subset
was signiﬁcantly lower in NFKB1 mutated patients when compared to
healthy controls (Fig. 3A andC). Furthermore, the CD56dimCD62L+ subset
was strongly reduced in NK cells from patients with NFKB1mutations
when compared to healthy controls, both in terms of percentages and
MFI (Fig. 3A andD). These data suggest that the canonical NF-κBpathway
orchestrates unique aspects of human NK cell maturation stages.
Evaluation of activating (CD16) and chemokine (CXCR1, CCR7)
receptors further revealed the involvement of the canonical pathway
in human peripheral NK cell maturation/homeostasis (Fig. 4). The
percentage of CD56dim NK cells expressing CXCR1 were signiﬁcantly
reduced in NFKB1 mutated patients as compared to healthy controls
(Fig. 4A). The percentage of CD56bright NK cells expressing CCR7
(Fig. 4B) was variable among the NFKB1 mutated patients, similarly as
observed in the healthy controls. The percentages of CD56+NK cells ex-
pressing CD16 were similar between NFKB1 mutated patients and
healthy controls (Fig. 4C). Interestingly, CD16 showed reduced MFI in
patients with NFKB1 mutations compared to the healthy controls
(Fig. 4C). The expression of the remaining NK cell receptors was normal
(Supplementary Fig. 1). In summary, these data provide evidence for an
essential role of NFKB1 in human NK cell maturation.
3.3. Impaired in vitro degranulation of NK cells derived from patients with
NFKB1 mutations
Our results indicated that NK cell maturation was perturbed in the
presence of monoallelic NFKB1mutations. Based on previous published
data from mice studies [7] and on our previous observations in NK cells
derived from a patient with a heterozygous NFKB2 mutation [12], we
next investigated the functional consequences of NFKB1 mutations in
human NK cell biology. Baseline degranulation against the human
erythroleukemia cell lineK562,measured asCD107a expressionof resting
NK cells [18], was similar in both test groups (NFKB1: 19.33%mean value,n=6; healthy controls: 24.12%mean value, n=10) (Fig. 5A upper panel
andB). Upon IL-2 stimulation in vitro (Fig. 5A lower panel and5B), NK cell
degranulation against the human erythroleukemia cell line K562was sig-
niﬁcantly reduced in cells carrying NFKB1 mutations (44.66%; n = 6;
p b 0.005) when compared to healthy controls (60.71%; n = 10). These
data collectively provide evidence for a novel role for the canonical path-
way in human NK cell degranulation similar to the previously described
involvement of the non-canonical pathway [12].
3.4. NK cells fail to produce Interferon-γ in the presence of monoallelic
NFKB1 mutations
Based on our ﬁndings on the implication of the canonical NF-κB path-
way in human NK cell maturation and degranulation, as well as on stud-
ies in p50 deﬁcient mice [7], we next investigated whether IFN-γ
production, a prominent biological feature of NK cells, was also affected
due to the presence of monoallelic NFKB1mutations. We thus evaluated
the production of IFN-γ inNK cells derived frompatientswithNFKB1mu-
tations and age-matched healthy control donors upon simultaneous
stimulation with IL-12 plus IL-18 [19]. As expected, unstimulated NK
cells (Fig. 5C upper panel and 5D) in either test group did not produce
IFN-γ (NFKB1: 11%, mean value, n = 6; healthy donors: 8%, mean
value, n = 10). However, upon combined stimulation with IL12 and IL-
18 (Fig. 5C lower panel and D), IFN-γ production was signiﬁcantly re-
duced in NK cells from patients carrying NFKB1 mutations (32.43%,
mean value, n = 6, p b 0.001) when compared to age-matched healthy
control samples (72.83%, mean value, n = 10). These results collectively
suggest that NFKB1 plays a critical, previously unrecognized, role in IFN-γ
production upon in vitro NK cell stimulation with IL-12 and IL-18.
3.5. IL-2 activated NK cells from patients with NFKB1 mutations fail to up-
regulate the activation marker NKp44 and display impaired proliferative
capacity
Since NK cells derived from individuals carrying NFKB1 mutations
had an aberrant receptor proﬁle expression as well as impaired
Fig. 5. NK cell cytolytic activity and Interferon-γ production in the presence of monoallelic null NFKB1 mutations. A. NFKB1 mutated NK cells fail to up-regulate CD107a upon IL-2
stimulation against the human erythroleukemia cell line K562 when compared to a representative healthy control. B. Summarized data for CD107a up-regulation from healthy
controls (CTRs) (n = 10) and NFKB1 mutated patients (n = 6). C. Evaluation of IFN-γ production before (upper panel) and after (lower panel) stimulation with IL-12 and IL-18 in NK
cells from a healthy control and an NFKB1 mutated patient. D. Summarized data for IFN-γ production (shown as percentages of positive cells) from healthy controls (CTRs) (n = 10)
and NFKB1 mutated patients (n = 6). Data were obtained from single experiments performed in triplicate and statistical analysis was performed using the t-student test (* =
p b 0,05; ** = p b 0,005; *** = p b 0,0005; **** = p b 0,0001).
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IL-2 activated NK cell populations showed phenotypical or functional
alterations. We therefore evaluated the expression of the NK cell
activating receptor NKp44, a member of the NCR family together with
NKp46 andNKp3020. Expression of NKp30 in both, resting (Supplemen-
tary Fig. 1) and IL-2 activated NK cells (data not shown) was normal in
all analyzed samples. In contrast, the expression of the activating
receptor of NKp44 on IL-2 stimulated NK cells from patients with
NFKB1 mutations was strongly reduced and remained persistently
lower over a 4 weeks observation period (time points of evaluation:
14, 21 and 28 days) when compared to the controls (Fig. 6A). The
expression of NKp46, another member of the NCR family [20], was re-
duced in unstimulated NK cells from patients with NFKB1 mutations
(Fig. 2B), and remained unaffected upon IL-2 stimulation after 21 days
of IL-2 stimulation (Fig. 6B), suggesting that the canonical NF-kB
pathway plays a distinct role on the expression of activation markers,
such as NKp44, on human NK cells.
We furthermore evaluated the intracellular expression of Ki-67 as an
index of the proliferative capacity of IL-2 activatedNK cells derived from
patients with NFKB1mutations and healthy controls. The proliferative
responses upon IL-2 activation of NK cells harboring NFKB1mutations
were impaired as compared to healthy controls (Fig. 6C). The decreased
response was not related to cell apoptosis (Fig. 6D) and surface expres-
sion levels of IL2R were normal (data not shown). These observations
suggest the involvement of NFKB1 in IL-2 dependent human NK cell
proliferative response.4. Discussion
The two NF-κB pathways, canonical and non-canonical, play an im-
portant role in immune cell biology. Although diverse in terms of com-
ponents and type of activating stimuli, both pathways have been shown
to play crucial roles in distinct biological functions of immune cells
[1–3]. This diversity has been studied mainly in mouse models and
mainly for B and T lymphocytes [1,4]. Data on the involvement of NF-
κB in NK cell function and maturation are limited. Regarding the
NFKB1-dependent canonical pathway, studies in p50-deﬁcient knock-
out mice suggested that p50 is a negative regulator of NK cell prolifera-
tion and IFN-γ production [7]. However, little is known about the in-
volvement of NFKB1 in human NK cell biology in terms of maturation
and effector functions. In the present study, we analyzed NK cells de-
rived from patients with mutations in NFKB1 as an “experimentum
naturae” model and provide the ﬁrst evidence for an essential role for
NFKB1 in human NK cell biology.
Human NK cell maturation appeared to be impaired in the presence
of monoallelic NFKB1 mutations. Whereas patients with NFKB1
mutations showed normal numbers of peripheral NK cells, mutant
NK cells showed reduced expression of NKp46, KIRs and CD57. Regard-
ing CD57 in particular, a classical maturation marker [17], while the
CD56dimCD57lo NK cell subset occurred normal, NK cells with NFKB1
mutations presented a signiﬁcant reduction of the CD56dimCD57hi pop-
ulation when compared to healthy controls. Previously published data
[21–22] have shown that high CD57 expression levels, co-expressed
Fig. 6. Evaluation of IL-2 activated human NK cells from NFKB1 mutated patients. A. Expression of NKp44 on IL-2 activated NK cells from NFKB1 mutated patients (Pt. 1 and Pt. 2) and a
representative healthy control evaluated at day 14 (14 d), 21 (21 d) and 28 (28 d) after stimulation. B. Expression of NKp46 on IL-2 activated NK cells fromNFKB1mutated patients (Pt. 1
and Pt. 2) and a representativehealthy control evaluated at day 21 (21 d) after stimulation. C. Evaluation of theproliferative capacity of IL-2 activatedNK cells fromNFKB1mutatedpatients
(Pt. 1 and Pt. 2) and a representative healthy control as measured by Ki-67 intracellular expression at day 14 (14 d) and 21 (21 d) after stimulation. D. Evaluation of NK cells undergoing
apoptosis of IL-2 activated NK cells from an NFKB1 mutated patient (Pt. 2) and a representative healthy control as measured by Ki-67 intracellular expression at day 14 (14 d) after
stimulation. Data shown are representative of three independent experiments (3 different healthy controls were tested).
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for CD56dim NK cells and depict a human viral memory NK cell subset,
which lacks in NK cells derived from patients with mutations in
NFKB1. Exposure to CMV has been shown to up-regulate CD57 and
NKG2C on human NK cells [23–24]. Within this cohort of patents, only
one patient presented an infection from CMV. Thus, while the majority
of the patients included in this study (6/7) resulted negative for CMV in-
fection, it is not yet knownwhether the viral infections that were docu-
mented in the NFKB1mutated patients, i.e. herpes zoster (4/7), JC virus
(1/7), Norovirus (1/7) or EBV (2/7), may up-regulate the above men-
tioned markers in human NK cells. These observations underline a di-
rect and speciﬁc role for the canonical pathway in this maturation
step of human NK cells.The chemokine receptors onNK cellswith heterozygousNFKB1muta-
tions showed variable expression of CCR7, but clearly reduced expression
of CXCR1 and CD62L. Regarding the latter, NK cells from patients with
NFKB1 mutations showed an expansion of the CD56brightCD62Llow
subset and a severe reduction of the CD56dimCD62L+ subset when com-
pared to healthy controls. This particular subset of CD56dimCD62L+
NK cells has been well studied [25] and represents an intermediate
stage of NK cell maturation with multiple functional capacities that
can develop into terminally differentiated effectors with elevated capa-
bility of IFN-γ production [25]. Therefore, these data provide further evi-
dence for a speciﬁc involvement of the canonical NF-κB signaling in
human NK cell maturation that may also underlie defective IFN-γ
production.
Fig. 7. Summaryof NK cell defects in primary immunodeﬁciencies (PIDs) due tomutations
in components of the NF-kB pathway. The asterisk (*) refers to the data presented in the
current study.
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in IL-2 stimulated NK cells derived from affected patients with NFKB1
mutations. These ﬁndings indicate an important role for NFKB1 in this
process in humans, similarly to what we observed in human NK cells
with defective NFKB2-dependent signaling [12].
Stimulation of NK cells from affected patients with IL12 plus IL-18
in vitro, resulted in impaired production of IFN-γ, hence revealing
another important regulatory role for NFKB1 in human NK cell
biology. This functional impairment may be related to the reduction of
the CD56dimCD62L+ NK cell population [25] which we observed in pa-
tients carrying NFKB1mutations. Interestingly, the defective IFN-γ pro-
duction of NFKB1 mutated NK cells is in contrast with observations in
the p50-deﬁcient knockout mice [7], which show enhanced IFN-γ re-
sponses, suggesting differences between patients with heterozygous
NFKB1mutations and mice with complete loss of both Nfkb1 alleles.
Further evaluation of IL-2 dependent human NK cell responses
showed that NK cells with heterozygous NFKB1 mutations failed to
up-regulateNKp44, an importantmember of theNCR family, suggesting
that the canonical pathway contributes to IL-2 induced human NK cell
activation. The reduced proliferative capacity observed upon in vitro
stimulation of NK cells with IL-2, is in contrast with observations in
p50-deﬁcient mice [7], and points toward involvement of the canonical
NF-κB pathway in IL-2-dependent NK cell activation and reveals further
differences between the patients carrying heterozygous NFKB1
mutations and mice with complete loss of both alleles.
Available data on the clinical presentation and possible complications
of CVID patients harboring NFKB1mutations are limited [13]. Besides an
increased proportion of autoimmune multiorgan manifestations, which
is consistent with observations in p50-deﬁcient mice [26], our cohort of
patients with heterozygous NFKB1mutations presents with an increased
prevalence of viral infections, including herpes zoster, JC virus, CMV,
Norovirus and EBV, a ﬁnding which has previously not been described
and which may indicate a broader susceptibility to viral infections
in this disorder. Recently, another patient with NFKB1 haploinsufﬁciency
was recently reported with EBV-driven lymphoproliferation, further
suggesting a susceptibility to viral infections in NFKB1 mutated
patients [27].Taken together, our ﬁndings deﬁne a novel intrinsic role for NFKB1
in human NK cell maturation and effector functions. Furthermore, our
data broaden the spectrum of NF-κB related PIDs with NK cell defects
(Fig. 7) and indicate that longer follow-up examinations and larger co-
horts of patients are required for a better characterization of the clinical
implications of human NK cell impairment in the presence of heterozy-
gous NFKB1mutations.
5. Conclusions
In this study,we provide evidence thatmonoallelic NFKB1mutations
affect human NK cell homeostasis in terms of maturation and effector
functions. NFKB1mutatedNKcells showed impaired peripheralmatura-
tion with a signiﬁcant reduction of the CD56dimCD57hi, CD56dimCD62L+
NK cell subsets, as well as altered expression pattern of NKp46, KIRs,
CXCR1, CCCR7 and CD16. Furthermore, NFKB1mutated NK cells showed
functional impairments in terms of cytotoxicity, IFN-γ production,
NKp44 up-regulation and proliferation. From a clinical point of view,
NFKB1 haploinsufﬁcient patients show a high prevalence of viral infec-
tions. Taken together, our data suggest an important, novel role for
NFKB1, thus for the canonical NF-kB pathway, in human NK cell biology
and human disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.clim.2016.11.012.
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